文献速递造血干细胞移植与细胞治疗

HLA相合同胞或无关供者骨髓移植后使用移植后环磷酰胺的免疫抑制负担较低

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.
PubMed 文献 · Blood · 2017-01-03

该研究评估339例接受HLA相合同胞(MRD)或无关(MUD)供者骨髓移植并使用移植后环磷酰胺(PTCy)单药预防GVHD患者的纵向免疫抑制需求。约50%的MRD患者和30%的MUD患者除PTCy外从未需要额外免疫抑制;需要进一步免疫抑制者通常仅需1至2种药物,中位持续时间为4.5至5个月。研究提示PTCy可降低HLA相合异基因骨髓移植患者的整体免疫抑制负担。

要点

  • 约50%的MRD患者和30%的MUD患者除PTCy外从未需要额外免疫抑制。
  • 需要进一步免疫抑制者通常仅需1至2种药物,中位持续时间为4.5至5个月。
  • BuCy MRD、BuFlu MRD、BuCy MUD和BuFlu MUD组1年无系统免疫抑制生存概率分别为61%、53%、53%和51%。

核心结论

  • 这些数据提示PTCy可减少接受HLA相合异基因骨髓移植患者的整体免疫抑制负担。

研究设计与样本

  • 评估339例接受HLA相合同胞(MRD)或HLA相合无关(MUD)供者T细胞充足骨髓移植并使用PTCy单药预防GVHD患者的纵向免疫抑制治疗需求。
  • 247例接受白消安/环磷酰胺(BuCy)预处理(数据回顾性收集),92例接受白消安/氟达拉滨(BuFlu)预处理(数据前瞻性收集)。

主要发现

  • 约50%的MRD患者和30%的MUD患者除PTCy外从未需要免疫抑制。
  • 需要进一步免疫抑制的患者通常仅需1至2种药物。
  • BuCy MRD、BuFlu MRD、BuCy MUD和BuFlu MUD组系统药理免疫抑制的中位持续时间均为4.5至5个月。
  • BuCy MRD、BuFlu MRD、BuCy MUD和BuFlu MUD组1年存活且停用全部系统免疫抑制的概率分别为61%、53%、53%和51%。
  • BuCy MRD、BuFlu MRD、BuCy MUD和BuFlu MUD组3年存活且停用全部系统免疫抑制的概率分别为53%、48%、49%和56%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The intensive and prolonged immunosuppressive therapy required to prevent or treat graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) puts patients at substantial risk for life-threatening infections, organ toxicity, and disease relapse. Posttransplantation cyclophosphamide (PTCy) can function as single-agent GVHD prophylaxis after myeloablative, HLA-matched related (MRD), or HLA-matched unrelated (MUD) donor T-cell-replete bone marrow allografting, obviating the need for additional prophylactic immunosuppression. However, patients who develop GVHD require supplemental treatment. We assessed the longitudinal requirement for immunosuppressive therapy in 339 patients treated with this transplantation platform: 247 receiving busulfan/cyclophosphamide (BuCy) conditioning (data collected retrospectively) and 92 receiving busulfan/fludarabine (BuFlu) conditioning (data collected prospectively). Approximately 50% of MRD patients and 30% of MUD patients never required immunosuppression beyond PTCy. In patients requiring further immunosuppression, typically only 1 to 2 agents were required, and the median durations of systemic pharmacologic immunosuppression for the BuCy MRD, BuFlu MRD, BuCy MUD, and BuFlu MUD groups all were 4.5 to 5 months. For these 4 groups, 1-year probabilities of being alive and off all systemic immunosuppression were 61%, 53%, 53%, and 51% and 3-year probabilities were 53%, 48%, 49%, and 56%, respectively. These data suggest that PTCy minimizes the global immunosuppressive burden experienced by patients undergoing HLA-matched alloBMT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kanakry CG, Bolaños-Meade J, Kasamon YL, et al. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017. PMID: 28049637. doi:10.1182/blood-2016-09-737825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。